Jasper Therapeutics ( NASDAQ: JSPR ) reported data from the first three people in a phase 1/2 trial evaluating the addition of monoclonal antibody briquilimab to an existing bone marrow transplantation regimen in patients with sickle cell disease (SCD) and beta thalassemia considered at high risk for complications from or ineligible for standard myeloablative hematopoietic stem cell transplant.
The company said the addition of briquilimab (formerly JSP191) is being studied as a potential way to achieve a higher percentage of healthy donor stem cell engraftment (donor chimerism) without increased toxicity.
In the study, briquilimab was added to the regimen consisting of alemtuzumab, low-dose irradiation, and sirolimus prior to infusion of mobilized peripheral blood cells from human leukocyte-antigen matched related donors.
The company said all three sickle cell study participants treated with briquilimab successfully engrafted and no briquilimab-related severe adverse events were seen.
Participant 1 achieved neutrophil engraftment at 12 days after transplant and platelet engraftment at 17 days after transplant, while the second participant achieved neutrophil engraftment at 12 days and platelet engraftment at 10 days.
Participant 3 achieved neutrophil engraftment at 16 days and platelet engraftment at 8 days.
The main goal of the trial is to determine if the addition of briquilimab would increase the proportion of patients with donor myeloid chimerism ?98% at 1-year post-transplant.
The company said that the first two participants with peripheral blood chimerism achieved 100% donor myeloid chimerism at 60 days post-transplant.
At five months post-transplant, the first person treated with briquilimab has a total hemoglobin of 13.3 g/dL, increased from 8-9 g/dL at baseline, according to the company.
JSPR +106.83% to $1.00 premarket Jan. 3
For further details see:
Jasper stock surges 100% as drug shows promise in phase 1/2 trial for blood disorders